A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.

NCT03966651 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
1
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Institut Claudius Regaud

Collaborators